Alzheimer's Disease: Pharmacological Treatment and Management

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Clinical Neuropsychologist

• Publication date

  2000-02-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1076/1385-4046(200002)14:1;1-8;FT093PMID 10855063
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CE: Antipsychotic Medications

  2017cited by this paper
• A randomized controlled trial of prednisone in Alzheimer’s disease

  2000cited by this paper
• Fear recognition deficits after focal brain damage

  2000cited by this paper
• Inflammation and Alzheimer's disease.

  2000cited by this paper
• Cholinesterase inhibitors: A new class of psychotropic compounds.

  2000cited by this paper
• Estrogen for Alzheimer’s disease in women

  2000cited by this paper
• A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia

  1999cited by this paper
• Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group.

  1999cited by this paper
• Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

  1999cited by this paper
• The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.

  1999influential reference
• Metrifonate: update on a new antidementia agent.

  1999cited by this paper
• The efficacy, safety, and tolerability of antipsychotics in the elderly.

  1999cited by this paper
• Evaluation and management of aggressive behavior in the elderly demented patient.

  1999cited by this paper
• Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.

  1999cited by this paper
• The effects of clozapine on cognitive functioning in schizophrenia.

  1999cited by this paper
• Pharmacologic management of psychosis in dementia.

  1999cited by this paper
• Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

  1999cited by this paper
• Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

  1999cited by this paper
• The neurobiology and pharmacotherapy of Alzheimer's disease.

  1999cited by this paper
• Antipsychotics from theory to practice: integrating clinical and basic data.

  1999cited by this paper
• Valproic Acid Treatment of Agitation in Dementia

  1998cited by this paper
• Evaluating response to metrifonate.

  1998cited by this paper
• Treatment of the refractory schizophrenic patient.

  1998cited by this paper
• Alzheimer's disease management.

  1998influential reference
• A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

  1998cited by this paper
• Psychopharmacology of noncognitive abnormal behaviors in Alzheimer's disease.

  1998influential reference
• Developing Treatment Guidelines for Alzheimer's Disease and Other Dementias.

  1998cited by this paper
• Neuroendocrine evidence that clozapine's serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms.

  1998cited by this paper
• Cognitive function in nondemented older women who took estrogen after menopause

  1998cited by this paper
• Metrifonate: Overview of Safety and Efficacy

  1998influential reference
• Preclinical Pharmacology of Metrifonate

  1998cited by this paper
• Antidepressant response in late-life depression.

  1998cited by this paper
• Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia.

  1998cited by this paper
• Metrifonate treatment of the cognitive deficits of Alzheimer's disease

  1998cited by this paper
• Pharmacologic approaches to cognitive deficits in Alzheimer's disease.

  1998cited by this paper
• Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease

  1998cited by this paper
• New therapeutic approaches to cognitive impairment.

  1998influential reference
• Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.

  1998cited by this paper
• The pathogenesis of Alzheimer's disease.

  1998cited by this paper
• The treatment of psychosis in late life.

  1998cited by this paper
• Alzheimer's disease management.

  1998cited by this paper
• Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.

  1998cited by this paper
• Future therapeutic approaches to Alzheimer's disease.

  1998influential reference
• Pharmacokinetics and Drug Interactions of Cholinesterase Inhibitors Administered in Alzheimer's Disease

  1998cited by this paper
• Diagnosis and treatment of depression in patients with Alzheimer's disease and other dementias.

  1998influential reference
• The clinical interface of depression and dementia.

  1998influential reference
• Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease.

  1998cited by this paper
• Economic Considerations in Alzheimer's Disease

  1998cited by this paper
• The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances

  1998cited by this paper
• Propentofylline in the Treatment of Alzheimer’s Disease and Vascular Dementia: A Review of Phase III Trials

  1998cited by this paper
• Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors.

  1997cited by this paper
• Novel Neuroleptics Improve Attentional Functioning in Schizophrenic Patients: Ziprasidone and Aripiprazole

  1997cited by this paper
• A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial

  1997cited by this paper
• Treatment of agitation in dementia.

  1997influential reference
• Cognitive Impairment in Schizophrenia and Implications of Atypical Neuroleptic Treatment

  1997cited by this paper
• Alzheimer's disease: From gene to pathology

  1997cited by this paper
• Selective serotonin reuptake inhibitors and atypical antidepressants: A review and update for psychologists.

  1997cited by this paper
• The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.

  1997influential reference
• A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia.

  1997cited by this paper
• Behavioral treatment of depression in dementia patients: a controlled clinical trial.

  1997cited by this paper
• Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

  1997cited by this paper
• An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations.

  1997cited by this paper
• Excitotoxicity and neuroprotection.

  1997cited by this paper
• A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group.

  1997cited by this paper
• Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.

  1997cited by this paper
• A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease.

  1997cited by this paper
• Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease.

  1997cited by this paper
• A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia

  1997cited by this paper
• A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

  1997cited by this paper
• The role of estrogen in the treatment of Alzheimer's disease

  1997cited by this paper
• Fluvoxamine for Stereotypic Behavior in Patients with Dementia

  1997cited by this paper
• Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic.

  1997cited by this paper
• Treatment of Functional Decline in Adults with down Syndrome Using Selective Serotonin-Reuptake Inhibitor Drugs

  1997cited by this paper
• Clinical genetics, IV. Alzheimer's disease: from gene to pathology.

  1997cited by this paper
• Treatment of non‐cognitive symptoms in dementia

  1996cited by this paper
• Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer disease.

  1996cited by this paper
• The spectrum of behavioral changes in Alzheimer's disease

  1996cited by this paper
• The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.

  1996cited by this paper
• Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.

  1996cited by this paper
• Treatment strategies for agitation and psychosis in dementia.

  1996cited by this paper
• Moclobemide in Elderly Patients with Cognitive Decline and Depression: An International Double-blind, Placebo-controlled Trial

  1996cited by this paper
• A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease.

  1996cited by this paper
• Neuropsychiatric aspects of Alzheimer's disease

  1996cited by this paper
• A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease

  1996cited by this paper
• Serotonin-dopamine interaction and its relevance to schizophrenia.

  1996cited by this paper
• Treatment outcome in recurrent major depression: a post hoc comparison of elderly ("young old") and midlife patients.

  1996cited by this paper
• Effect of Tacrine on Behavioral Symptoms in Alzheimer's Disease: An Open-Label Study

  1996cited by this paper
• A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.

  1996cited by this paper
• Valproate in the treatment of behavioral agitation in elderly patients with dementia.

  1995cited by this paper
• AIT-082, a unique purine derivative, enhances nerve growth factor mediated neurite outgrowth from PC12 cells.

  1995cited by this paper
• Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes.

  1995cited by this paper
• Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

  1995cited by this paper
• Anticonvulsant and Other Non-neuroleptic Treatment of Agitation in Dementia

  1995cited by this paper
• Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine.

  1995cited by this paper
• The US economic and social costs of Alzheimer's disease revisited.

  1994cited by this paper
• Secreted forms of beta-amyloid precursor protein protect hippocampal neurons against amyloid beta-peptide-induced oxidative injury.

  1994cited by this paper
• A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease

  1994cited by this paper
• Treatment of Depression in Advanced Alzheimer's Disease Using Sertraline

  1994cited by this paper
• A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

  1994cited by this paper
• Effects of clozapine on cognitive function in schizophrenia.

  1994cited by this paper

• Alzheimer'S Disease: A Brief Quintessence Medical Management Study

  2015cites this paper
• A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia.

  2014cites this paper
• Memantine Therapy of Behavioral Symptoms in Community-Dwelling Patients with Moderate to Severe Alzheimer’s Disease

  2009cites this paper
• Safety and efficacy of psychopharmacological agents used to treat the psychiatric sequelae of common neurological disorders.

  2008cites this paper
• Safety and efficacy of psychopharmacological agents used to treat the psychiatric sequelae of common neurological disorders

  2008cites this paper
• Alzheimer’s Disease in Down Syndrome and Intellectual Disability: A Review

  2006cites this paper